CellSpring, a biotech spin-out from ETH Zurich incorporated in 2015, is evolving quickly. Today Tecan announced a co-marketing agreement to automate CellSpring’s 3D Bloom platform on Tecan’s Freedom EVO workstation.
The collaboration will further extend Tecan’s automated 3D cell culture portfolio, allowing scientists to take advantage of a high throughput technology with an extended cell viability period of at least seven days in the assay matrix.
The adaptive 3D Bloom Biopolymer Platform is compatible with all cell types and is ideal for both mono and co-culture assays. 3D microtissues can be prepared in microplate format within minutes, and analysis carried out while still in the culture matrix. Kevin Moore, Manager of Liquid Handling Products and Application Management, commented: “As a leader in the field of automated 3D cell culture, Tecan is delighted to be working with CellSpring to implement its microplate-based 3D Bloom platform on the Freedom EVO. This will allow scientists to benefit from straightforward, high throughput automation of a 3D cell culture process offering long-term cell viability.”
Dr Chris Millan, Chief Technology Officer at CellSpring, added: “CellSpring is excited to partner with Tecan to bring automated, simple 3D cell culture solutions to customers. The benefits of our 3D Bloom Platform – versatility and reliability – are now available at scale using the Freedom EVO.”
About Tecan
Tecan is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, forensic and diagnostic laboratories. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2015, Tecan generated sales of CHF 440 million (USD 459 million; EUR 411 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange
(SK)
Please login or sign up to comment.
Commenting guidelines